Abstract: Objective To observe the clinical effect and safety differences of paclitaxel liposome or paclitaxel injection combined with cisplatin in patients with middle and advanced cervical cancer. Methods 83 cases of patients with middle and advanced cervical cancer from June 2009 to June 2010 in our hospital were enrolled as study subjects and randomly divided into two groups, 42 cases in observation group and 41 cases in control group. Observation group was given paclitaxel liposome 135 mg·m^-2 via intravenous drip on the first day, cisplatin 60 mg·m^-2 was given via intravenous drip on the second day; control group was given paclitaxel injection 135 mg·m^-2 via intravenous drip on the first day, cisplatin 60 mg·m^-2 was given via intravenous drip on the second day. The two groups all took concurrent radiochemotherapy scheme. The clinical effect (recent curative effect and the forward curative effect) and safety differences between two groups in the treatment of cervical cancer were compared. Results The effective alleviation rates of observation group and control group were 83.33% and 68.29% respectively, the difference was statistically significant (P<0.05). The cervical cancer invasion and lymph node metastasis of observation group was significantly lower than control group, and the 5-year survival rate of the observation group was significantly higher than the control group (P<0.05). The adverse drug reaction such as alopecia, gastrointestinal reaction, anaphylactic reaction, myelosuppression and weakened immunity in observation group has significant differences compared with the control group (P<0.05). Conclusion In this study, paclitaxel liposome combined with cisplatin has good recent curative effect and forward curative effect and safety is relatively high in the treatment of cervical cancer.

Key words: paclitaxel liposome, paclitaxel injection, cisplatin, cervical cancer